Biomolecule Conjugates with Non-Natural Amino Acids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody development processes face challenges in improving the efficacy and minimizing undesirable side effects of immunoconjugate therapy, particularly in targeted cancer treatment, where existing methods struggle to effectively deliver cytotoxic agents to cancer cells while minimizing toxicity to healthy tissues.
Innovation Solution
The development of biomolecule conjugates that incorporate non-natural amino acids, specifically azide-containing amino acids, which are used to attach cytotoxic agents via a linker through a cycloaddition reaction, allowing for targeted and specific delivery of cytotoxic payloads to cancer cells using monoclonal antibodies or cell-binding agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional chemical linkers are used to attach cytotoxic agents to monoclonal antibodies, then the conjugation process is simpler, but the targeting precision and reduced nonspecific toxicity are compromised
Solution Approach 1:
The conjugation process is divided into two independent stages: first incorporating non-natural amino acids (with azide or strained alkyne groups) into the monoclonal antibody at specific positions, then separately attaching the cytotoxic agent via cycloaddition reaction. This segmentation allows each step to be optimized independently, achieving high targeting precision through site-specific incorporation while managing process complexity through modular design.
Solution Approach 2:
Non-natural amino acids with reactive groups (azide or strained alkyne) serve as intermediary linkers between the monoclonal antibody and the cytotoxic agent. These intermediaries enable site-specific attachment at defined positions on the antibody, ensuring precise targeting while reducing nonspecific binding. The intermediary approach allows controlled conjugation with improved manufacturing precision compared to conventional random attachment methods.
2Reliability
If conventional antibody-drug conjugates are used, then the production process is more straightforward, but the therapeutic efficacy and reduced side effects are limited
Solution Approach 1:
The monoclonal antibody is modified at specific local positions with non-natural amino acids, creating sites with unique chemical properties (azide or strained alkyne groups). This local quality modification enables site-specific conjugation of cytotoxic agents, ensuring that the drug is attached at optimal positions for maximum therapeutic efficacy while minimizing damage to healthy tissues. The localized modification approach provides superior control over conjugate homogeneity and biological activity.
Solution Approach 2:
The invention creates a composite structure combining monoclonal antibodies, non-natural amino acid linkers, and cytotoxic agents into a unified immunoconjugate. This composite material integrates the targeting capability of the antibody with the therapeutic potency of the cytotoxic agent through a stable, site-specific linker, achieving enhanced therapeutic efficacy and reduced side effects compared to conventional ADCs.
3Object-affected harmful factors
If site-specific incorporation of non-natural amino acids is implemented, then the targeted delivery is improved, but the manufacturing complexity increases
Solution Approach 1:
The reactive functional groups (azide or strained alkyne) are extracted as separate non-natural amino acid components that can be incorporated into the monoclonal antibody at defined positions. This extraction approach allows the antibody to be modified with precise control over the type and position of reactive groups, enabling targeted delivery while managing conjugation complexity through standardized, modular modification steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the targeted delivery of cytotoxic agents to cancer cells, reducing nonspecific toxicities and increasing therapeutic efficacy by utilizing the selective binding of monoclonal antibodies to cancer-specific antigens, thereby improving treatment outcomes while minimizing harm to healthy cells.
Implementation Method 1
conjugates of cell-binding agents and cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.